Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 36M | 3.2% |
| Net Income | -33M | 1.9% |
| EBITDA | -36M | 3.2% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 282M | 9.2% |
| Total Liabilities | 21M | 1.5% |
| Total Equity | 261M | 9.9% |
| Shares Outstanding | 58M | 0% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -36M | 6% |
| Cash from investing | 58M | 102.9% |
EPS
Financial Highlights for Astria Therapeutics in Q2 '25
Operating Expenses for this period were 36M, showing a -3.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -33M, showing a 1.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -36M, showing a 3.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
